Eli Lilly’s Oral Obesity Drug Trial Reaches Completion, Sharpening Investor Focus on LLY
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The study A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes tests Eli Lilly’s oral obesity drug in adults with excess weight. It aims to show how much the drug can reduce body fat versus placebo, giving early insight into its potential in the fast-growing obesity market.
The treatment under review is orforglipron, also known as LY3502970, taken by mouth. It is designed to help people with obesity or overweight lower body fat and improve weight control without needing injectable drugs.
The trial is an interventional Phase 1 study where participants are randomly assigned to orforglipron or a placebo. It is double-blind, meaning neither patients nor researchers know who gets which treatment, and its main goal is to assess treatment impact on body composition.
The study ran for about 8 months per participant and has an overall status of completed, signaling key data are now in hand. It was first submitted on 2025-01-27 and last updated on 2026-02-24, showing that Eli Lilly has recently refreshed the record as it processes and analyzes results.
For investors, the completion and recent update of this obesity study may support the long-term growth story for Eli Lilly’s weight-loss franchise and help sentiment toward LLY stock. Any indication that an oral option like orforglipron is effective could strengthen Lilly’s position against rivals in obesity care and broaden its reach beyond injectable treatments.
The study record for orforglipron in adults with obesity or overweight is now completed and recently updated, and more detailed information is available on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.
